Sign In
Buy ASH
$57.00
-0.580 (-1.01%)
At Close: Jun 03, 2026
NEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and co
All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
11:30am, Saturday, 07'th Dec 2024
ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the selection of 10 abstracts for poster presentations and two ab
Bagsværd, Denmark, 3 December 2024 – Novo Nordisk today announced the presentation of 13 abstracts, three of which will be presented in oral sessions, at the upcoming 66th Annual Meeting and Exposi
Results collectively support the mechanism of action and rationale for targeting MMSET in patients with multiple myeloma CAMBRIDGE, Mass. , Dec. 3, 2024 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36")
SEATTLE, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst
Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024
01:00am, Tuesday, 03'rd Dec 2024
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that abstracts related to lacutam
Kura Oncology to Host Virtual Investor Event on December 9, 2024
07:30am, Monday, 02'nd Dec 2024
Live webcast and conference call to discuss presentation of updated data from KOMET-007 combination trial of ziftomenib at ASH Live webcast and conference call to discuss presentation of updated data
SAN FRANCISCO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat pati
New Strong Sell Stocks for November 26th
07:40am, Tuesday, 26'th Nov 2024
AHEXY, WMS and ASH have been added to the Zacks Rank #5 (Strong Sell) List on November 26, 2024.
75% (12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of therapy Data will be presented on Monday, December 9, 2024 at 4:00 PM PT LOS ANG
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for approved and investigational medicines across mu
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASH--BMS' Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms.
Ashland board authorizes quarterly dividend
07:00am, Thursday, 14'th Nov 2024
WILMINGTON, Del., Nov. 14, 2024 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock. T
